OncLive TV

Dr. Cohen on the Importance of Patient Selection for HIPEC Surgery in CRC

September 9th 2021

Stacey A. Cohen, MD, discusses the importance of patient selection for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in colorectal cancer.

Dr. Robert on Evaluating Trends in Biomarker Testing in Metastatic NSCLC

September 9th 2021

Nicholas Robert, MD, discusses the importance of evaluating trends in biomarker testing in metastatic non–small cell lung cancer.

Dr. Blakely on Utilizing Osimertinib in Resectable EGFR-Mutant NSCLC

September 9th 2021

Collin Blakely MD, PhD, discusses the rationale for utilizing osimertinib in resectable EGFR-mutant non–small cell lung cancer.

Dr. Danilov on the Utility of BTK Inhibitors in CLL

September 8th 2021

Alexey V. Danilov, MD, PhD, discusses the utility of BTK inhibitors as a treatment option for patients with chronic lymphocytic leukemia.

Dr. Patel on the Integration of CAR T-Cell Therapy in Multiple Myeloma

September 8th 2021

Krina K. Patel, MD, MSc, discusses the integration of CAR T-cell therapy into the treatment paradigm of relapsed/refractory multiple myeloma.

Dr. Raghav on First-Line Treatment Options in CRC

September 7th 2021

Kanwal Raghav, MBBS, MD, discusses first-line treatment options for patients with colorectal cancer.

Dr. Zhen on Advancements in Gastroenteropancreatic Neuroendocrine Tumors

September 7th 2021

David Zhen, MD, discusses advancements in the treatment of patients with gastroenteropancreatic neuroendocrine tumors.

Dr. Abdul Razak on Initial Findings With Durvalumab Plus Olaparib or Cediranib in Leiomyosarcoma

September 7th 2021

Albiruni Ryan Abdul Razak, MRCP, MBBCh, discusses initial findings from a phase 2 trial evaluating the utility of durvalumab in combination with olaparib or cediranib in leiomyosarcoma.

Dr. Ready on Selecting Between Frontline Atezolizumab and Durvalumab in ES-SCLC

September 7th 2021

Neal E. Ready, MD, PhD, discusses selecting between frontline chemotherapy plus atezolizumab or durvalumab in extensive-stage small cell lung cancer.

Dr. Parikh on Future Research Directions in Hepatitis C-Related HCC

September 7th 2021

Neehar Parikh, MD, discusses future research directions in hepatitis C-related hepatocellular carcinoma.

Dr. Llovet on Considering Safety Profiles During Treatment Selection in HCC

September 7th 2021

Josep Llovet, MD, discusses the adverse events cause by treatments in hepatocellular carcinoma.

Dr. Pinato on Guidelines for Toxicity Management in HCC

September 5th 2021

David J. Pinato, MD, discusses guidelines for toxicity management in hepatocellular carcinoma (HCC).

Dr. Vogel on the Utility of Frontline Lenvatinib or Sorafenib in HCC

September 4th 2021

Arndt Vogel, MD, discusses the utility of frontline lenvatinib or sorafenib in hepatocellular carcinoma.

Dr. Singal on the Results of a Mailed Outreach Strategy for Surveillance Utilization in HCC

September 4th 2021

Amit Singal, MD, discusses the results of a study evaluating the utilization of a mailed surveillance outreach program in hepatocellular carcinoma.

Dr. Mogal on the Incidence and Prognosis of Peritoneal Carcinomatosis in CRC

September 3rd 2021

Harveshp D. Mogal, MD, MS, FACS, DABS, FSSO, discusses the incidence and prognosis of peritoneal carcinomatosis in colorectal cancer.

Dr. Dietrich on Future Research Directions in Lung Cancer

September 3rd 2021

Martin Dietrich, MD, PhD, discusses future research directions for the treatment of patients with lung cancer. 

Dr. Van Rhee on Future Research Directions for CAR T-Cell Therapy in Multiple Myeloma

September 3rd 2021

Frits van Rhee, MD, PhD, discusses future research directions with CAR T-cell therapy for the treatment of patients with multiple myeloma.

Dr. Castillo on the Integration of BTK Inhibitors in Waldenström

September 3rd 2021

Jorge J. Castillo, MD, discusses the integration of BTK inhibitors in Waldenström macroglobulinemia.

Dr. Herrera on the Utility of CAR T-Cell Therapy in Hematologic Cancers

September 3rd 2021

Alex Herrera, MD, discusses the utility of CAR T cells in patients with hematologic cancers.

Dr. Harris on IMbrave150 Results With Atezolizumab/Bevacizumab in HCC

September 3rd 2021

William P. Harris, MD, discusses updated data from the phase 3 IMbrave150 study in hepatocellular carcinoma.